Abstract:Objectives This study aimed to explore the relationship between plasma proteome and the clinical features of Major Depressive Disorder (MDD) during treatment of acute episode. Methods In this longitudinal observational study, 26 patients hospitalized for moderate to severe MDD were analyzed. The study utilized Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) alongside clinical metrics, including symptomatology derived from the Montgomery-Åsberg Depression Rating Scale (MADRS). Plasma protein analysis was conducted at the onset of acute depression and 6 weeks into treatment. Analytical methods comprised of Linear Models for Microarray Data (LIMMA), Weighted Correlation Network Analysis (WGCNA), Generalized Linear Models, Random Forests, and The Database for Annotation, Visualization and Integrated Discovery (DAVID). Results Five distinct plasma protein modules were identified, correlating with specific biological processes, and uniquely associated with symptom presentation, the disorder’s trajectory, and treatment response. A module rich in proteins related to adaptive immunity was correlated with the manifestation of somatic syndrome, treatment response, and inversely associated with achieving remission. A module associated with cell adhesion was linked to affective symptoms and avolition, and played a role in the initial episodes and treatment response. Another module, characterized by proteins involved in blood coagulation and lipid transport, exhibited negative correlations with a variety of MDD symptoms and was predominantly associated with the manifestation of psychotic symptoms. Conclusion This research points to a complex interplay between the plasma proteome and MDD’s clinical presentation, suggesting that somatic, affective, and psychotic symptoms may represent distinct endophenotypic manifestations of MDD. These insights hold potential for advancing targeted therapeutic strategies and diagnostic tools. Limitations The study’s limited sample size and its naturalistic design, encompassing diverse treatment modalities, present methodological constraints. Furthermore, the analysis focused on peripheral blood proteins, with potential implications for interpretability.

Serum L-selectin levels as predictive markers for chronic major depressive disorder progression

Serum proteomic changes related to residual impairment in remittent depression are associated with immune and inflammatory processes

Blood Mir-144-3p: a Novel Diagnostic and Therapeutic Tool for Depression

Serum Exosome-Derived Mir-139-5p As a Potential Biomarker for Major Depressive Disorder

L-Carnitine and Acetyl-L-Carnitine: Potential Novel Biomarkers for Major Depressive Disorder

Predictors of recurrence of major depressive disorder

Serum Lipid Levels and Suicide Attempts Within 2 Weeks in Patients With Major Depressive Disorder: Is There a Relationship?

Identifying clinical and proteomic markers for early diagnosis and prognosis prediction of major psychiatric disorders

Serum proteomic analysis uncovers novel serum biomarkers for depression

Serum metabolomics of end-stage renal disease patients with depression: potential biomarkers for diagnosis

Correlating plasma protein profiles with symptomatology and treatment response in acute phase and early remission of major depressive disorder

Identifying Plasma Biomarkers with high specificity for major depressive disorder: A multi-level proteomics study

Increased Serum S100B Protein in Patients with Major Depression

Serum NLRP3 Inflammasome and BDNF: Potential Biomarkers Differentiating Reactive and Endogenous Depression

Serum levels of interleukin-33 and mesencephalic astrocyte derived neurotrophic factors in patients with major depressive disorder: a cross-sectional comparative design

Functional connectivity of salience and affective networks among remitted depressed patients predicts episode recurrence

The Combination of Serum BDNF, Cortisol and IFN-Gamma Can Assist the Diagnosis of Major Depressive Disorder

An Exploratory Pilot Study with Plasma Protein Signatures Associated with Response of Patients with Depression to Antidepressant Treatment for 10 Weeks

Integrating Functional Neuroimaging and Serum Proteins Improves the Diagnosis of Major Depressive Disorder.

Identification of depression in patients with acute coronary syndrome using multiple serum biomarkers

A Preliminary Investigation on Plasma Cell Adhesion Molecules Levels by Protein Microarray Technology in Major Depressive Disorder